top of page
ARDIA Full Logo .png

Orphan-First Pipeline

DIA-615 designed to efficiently advance from ex-vivo validation to clinical proof-of-concept
indication
Cutaneous Lupus Erythematosus (CLE)
Epidermolysis Bullosa Simplex (EBS)

Shared Biological Drivers

DIA-615 is being evaluated in skin conditions associated with cell-driven tissue damage:

noun-cell-8237968-3F6F64.png

Endoplasmic Reticulum Stress-Associated Dysfunction

noun-dna-structure-6754622-3F6F64.png

Altered Epigenetic Cell Differentiation

noun-skin-condition-and-dermatology-8376368-3F6F64.png

Imparied

Epidermal Barrier

Integrity

For partnership and investor inquiries:

Bjones@ardiatherapeutics.com
bottom of page